ArticleInternational journal of cardiology. Heart & vasculature2024
Impact of sodium glucose co-transporter-2 inhibitors on left atrial functions in patients with type-2 diabetes and heart failure with mildly reduced ejection fraction.
Article in International journal of cardiology. Heart & vasculature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effects of Dapagliflozin on Left Atrial Ejection Force in Heart Failure with Preserved Ejection Fraction: DAPA-Left Atrial Ejection Force Trial.Anatolian journal of cardiology · 2025Trial
- Article
- Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Left Ventricular Global Longitudinal Strain in Adults with Type 2 Diabetes Mellitus: A Systematic Review.Journal of clinical medicine · 2026Review
- Multi-Chamber Reverse Remodeling and Hemodynamic Force Realignment After SGLT2 Inhibitor Initiation in Real-World Heart Failure.Journal of cardiovascular development and disease · 2026Article
- Targeting epicardial adipose tissue in heart failure with preserved ejection fraction: exploring the dapagliflozin connection.BMC cardiovascular disorders · 2026Article
- The impact of dapagliflozin on left atrial functions and recurrence in non-diabetic patients in the early post-cryoablation period.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.Frontiers in endocrinology · 2026Article
- Right Ventricular-Pulmonary Artery Coupling Predicts Early Myocardial Strain Improvement in SGLT2 Inhibitor-Treated HFrEF.Journal of the Saudi Heart Association · 2026Article
- Article
- Arrhythmia-Induced Cardiomyopathy in Atrial Fibrillation: Pathogenesis, Diagnosis, and Treatment.Life (Basel, Switzerland) · 2025Review
- Clinical Applications of Speckle-Tracking Echocardiography in Heart Failure: From Diagnosis to Prognostication.International journal of heart failure · 2025Review
- Recent highlights from the International Journal of Cardiology Heart & Vasculature: cardiometabolic disease.International journal of cardiology. Heart & vasculature · 2025Article
- The left atrium in heart failure with preserved ejection fraction: What we know and what we do not know.Heart rhythm O2 · 2025Review
- Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics-insights from comprehensive CMR and serum biomarker analyses.Cardiovascular diabetology · 2025Article
- Diabetes and atrial fibrillation: Causality is still a black-box.International journal of cardiology. Heart & vasculature · 2025Article
- Left Atrial Strain-Current Review of Clinical Applications.Diagnostics (Basel, Switzerland) · 2025Review
- Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts.Journal of clinical medicine · 2025Review
- Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.International journal of molecular sciences · 2024Review
- Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling.Current issues in molecular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to assess the impact of adding sodium glucose co-transporters-2 inhibitors (SGLT-2I) on cardiac remodeling in type 2 diabetic patients with heart failure with mildly reduced ejection fraction (HFmrEF) that had been under-represented in most clinical trials through the analysis of left atrial (LA) phasic functions with 2-D speckle tracking echocardiography (2D- STE. Methods: We enrolled 70 patients with type 2 diabetes (T2DM) and stable HFmrEF (35 patients received one of SGLT-2I either empagliflozin or dapagliflozin). Laboratory assessment and echocardiographic evaluation were carried out at baseline and after 6 months. LA volumes and deformation analysis were conducted using 2D-STE. Three LA strain parameters were obtained (LA reservoir strain, contractile strain, and conduit strain). Results: After 6 months of SGLT-2 I treatment, there was better control of HbA1C and improvement of diastolic functions (E/e' ratio and LAV-I significantly decreased. P < 0.001*). LVGLS increased, LA functions and all LA strain curve values improved, LA reservoir increased from 17.3 ± 2.0 to 23.8 ± 3.6, LA conduit from 11.0 ± 2.2 to 13.7 ± 2.8 and LA contractile from 6.5 ± 1.4 to 10.5 ± 2.6, P < 0.001* for all. Changes in LA strain values were significantly associated with the changes in LVGLS, LAEF %, E/ e' ratio, and LAV-I. Conclusion: Adding SGLT-2I to existing guideline-directed medical therapy in patients with T2DM and HFmrEF is associated with favorable clinical outcomes and significant improvement of LA volume and functions, with further improvement of LV diastolic and longitudinal functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.